Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 11:15 PM
Ignite Modification Date: 2025-12-25 @ 8:53 PM
NCT ID: NCT03750656
Description: Study was terminated early therefore no data was collected to monitor/assess adverse events.
Frequency Threshold: 0
Time Frame: Not Applicable - Adverse events were not documented.
Study: NCT03750656
Study Brief: Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Hyoscyamine Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort Hyoscyamine: Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent 0 None 0 0 0 0 View
Tamsulosin 0.4 mg tab orally daily Tamsulosin: Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent 0 None 0 0 0 0 View
Serious Events(If Any):
Other Events(If Any):